Comments

Black Diamond Therapeutic Stock Price, Quotes and Forecasts

Q: What sector and industry does Black Diamond Therapeutic (BDTX) operate in?

Black Diamond Therapeutic is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

BDTXNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$1.68

-0.10-5.62%

At close: -

$1.66

-0.02-1.19%

After Hours: 7:59 PM EDT

Black Diamond Therapeutic (BDTX) Forecast

News Earnings Black Diamond Therapeutic (BDTX) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Black Diamond Therapeutic Stock Price, Quotes and Forecasts | NASDAQ:BDTX | Benzinga

Explore Black Diamond Therapeutic stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for BDTX.

Open	$1.75
Close	$1.68
Volume / Avg.	0 / 3.17M
Day Range	$1.64 - $1.80
52 Wk Range	1.59 - 7.66
Market Cap	$94.06M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	35
Short Interest	21.99%
Days to Cover	17.55

Recent News

Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone payments.

Vandana Singh

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug

Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows potential to address osimertinib resistance.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Oct 24

Nov 24

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$1.75
Close	$1.68
Volume / Avg.	0 / 3.17M
Day Range	$1.64 - $1.80
52 Wk Range	1.59 - 7.66
Market Cap	$94.06M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	35
Short Interest	21.99%
Days to Cover	17.55

About Black Diamond Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies t...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Black Diamond Therapeutic (BDTX) stock?

You can purchase shares of Black Diamond Therapeutic (NASDAQ:BDTX) through any online brokerage.

View our list of the best stock brokerages

Who are Black Diamond Therapeutic (BDTX) competitors?

Other companies in Black Diamond Therapeutic’s space includes: Zura Bio (NASDAQ:ZURA), Anixa Biosciences (NASDAQ:ANIX), Galectin Therapeutics (NASDAQ:GALT), Adverum Biotechnologies (NASDAQ:ADVM) and OncoCyte (NASDAQ:OCX).

What is the forecast, or price target, for Black Diamond Therapeutic (BDTX) stock?

Black Diamond Therapeutic has a consensus price target of $15.60.

What is the current price for Black Diamond Therapeutic (BDTX)?

The stock price for Black Diamond Therapeutic (NASDAQ: BDTX) is $1.66 last updated March 24, 2025 at 7:59 PM EDT.

Does Black Diamond Therapeutic (BDTX) pay a dividend?

There are no upcoming dividends for Black Diamond Therapeutic.

When is Black Diamond Therapeutic (NASDAQ:BDTX) reporting earnings?

Black Diamond Therapeutic’s Q1 earnings are confirmed for Thursday, May 8, 2025.

Is Black Diamond Therapeutic (BDTX) going to split?

There is no upcoming split for Black Diamond Therapeutic.

What sector and industry does Black Diamond Therapeutic (BDTX) operate in?

Black Diamond Therapeutic is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.